Navigation Links
Study Suggests Soy Protein May Reduce Prostate Cancer Risk

ST. LOUIS, Oct. 4 /PRNewswire/ -- A study published in the Oct. 1 Journal of Nutrition suggests consumption of soy protein may play a role in reducing the risk of prostate cancer, Solae notes, giving consumers another healthy reason to make soy part of their diet.

The study, "Soy protein isolate increases urinary estrogens and the ratio of 2:16 alpha-hydroxyestrone in men at high risk of prostate cancer," is believed to be the first study investigating the effects of soy protein consumption on estrogen metabolism and prostate cancer in men.

"The intent of the study was to evaluate the effects of consuming soy protein on elimination of estrogen metabolites in the urine of men at a high risk for prostate cancer," said Dr. Mindy Kurzer, lead author of the study and a professor in the Department of Food Science and Nutrition at the University of Minnesota. "After taking biopsies of prostate tissue, androgen receptors were reduced in the prostate, which is consistent with a reduced risk of prostate cancer. In addition, significantly fewer of the men who consumed soy protein progressed to cancer by the end of the six-month study. We are encouraged by the results, but more studies must be performed."

"The results of this study could be beneficial for men who are at risk of prostate cancer," said Dr. Kathryn Greaves, Group Lead, Clinical Nutrition at Solae. "If the results of this study are replicated in future studies, reducing the risk of prostate cancer may be another reason to include soy in your daily diet."

Soy has been documented to potentially improve heart health and aid in sports performance and weight management. For more information on Solae and its products, please visit

About Solae

Solae is the world leader in developing innovative soy-based technology to the food, meat and nutritional products industries. Solae provides solutions that deliver a unique combination of functional, nutritional and economic benefits to our customers.

Headquartered in St. Louis, Missouri, USA, with annual revenue exceeding $1 billion, the company was formed through an alliance between Bunge Limited (NYSE: BG) and DuPont (NYSE: DD). For more information, visit

Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:11/29/2015)... 29, 2015 CIVCO Medical Solutions will ... the Radiological Society of North America ... November 29 – December 4, 2015. ... offer customers unrivaled versatility, enhanced user experience and ... --> ...
(Date:11/27/2015)... 2015  Lannett Company, Inc. (NYSE: LCI ... acquisition of Kremers Urban Pharmaceuticals Inc. (KU), the ... company UCB S.A. (Euronext: UCB). ... KU from UCB for total consideration of approximately ... customary working capital adjustment, a deduction of certain ...
(Date:11/26/2015)... 26 november 2015 AAIPharma Services ... geplande investering aan van ten minste $15,8 ... en het mondiale hoofdkantoor in ... resulteren in extra kantoorruimte en extra capaciteit ... groeiende behoeften van de farmaceutische en biotechnologische ...
Breaking Medicine Technology:
(Date:11/29/2015)... St. Petersburg, FL (PRWEB) , ... November 30, 2015 , ... The Cyber Monday deal ... webstore. , It is the right time to get gifts for the skin care lover ... bow on top filled with serums . This year, the 3 serums are staples: Collagen, ...
(Date:11/29/2015)... PITTSBURGH, PA (PRWEB) , ... November 29, 2015 , ... ... assistance with kneeling or provide ready access to exercise weights. Fortunately, an inventor from ... prototype for THE TOMMY WALKER to enhance the benefits of a standard walker to ...
(Date:11/29/2015)... ... November 29, 2015 , ... Effective immediately, every single IguanaMed scrub ... on Black Friday Target is offering a “Buy One Scrub Set, Get the 2nd ... opportunity to purchase IguanaMed at a discounted price. , IguanaMed’s mission is ...
(Date:11/28/2015)... ... 28, 2015 , ... Safe storage for contraceptive devices may not always be ... New Jersey and the other from Bradley Beach, New Jersey, there is an easy ... of having to replace NuvaRings more often than necessary. As such, it affords peace ...
(Date:11/28/2015)... , ... November 28, 2015 , ... Pixel Film Studios ... media panels to choose from, the possibilities are endless. Users have full control over ... the ProPanel: Pulse masking effects, users are sure to get heads to turn. , ...
Breaking Medicine News(10 mins):